ACS Pharmacology & Translational Science plans to publish a special issue titled “Psychedelics: New Advances in Preclinical & Clinical Studies” in early 2021. Assistant Professor David Olson, University of California, Davis, Department of Chemistry and Department of Biochemistry & Molecular Medicine, is the guest editor for the special issue and invites you to submit a manuscript by November 15, 2020.
“Psychiatry is desperate,” says Olson, “and it is clear that if we ever hope to cure mental illness, we need to embrace truly innovative treatment approaches. The use of psychedelics in medicine could be a boon, as these drugs have shown promise for producing both rapid and long-lasting therapeutic effects across multiple neuropsychiatric disorders. Studies using these powerful drugs in combination with the tools of modern science will undoubtedly provide new insights into brain function, and hopefully, get us closer to finding effective medicines for depression, post-traumatic stress disorder, and substance use disorder.”
What to Submit—Deadline: November 15, 2020
“We’re looking for cutting-edge preclinical and human clinical data with psychedelic drugs,” says ACS Pharmacology & Translational Science Editor-in-Chief Craig Lindsley. “Without question, the resurgence of psychedelics represents the most exciting neurotherapeutic area in decades!”
Areas of particular interest include:
- The effects of psychedelics in preclinical models of brain disorders
- Detailed pharmacological and/or DPMK characterization of known and designer psychedelics
- New insights into the molecular mechanisms of psychedelics
- Human clinical data with psychedelics
Articles, Letters, Reviews, Perspectives, and Viewpoints are all welcome. For details on requirements for each manuscript type, please consult the Author Guidelines. You can also find the entire ACS Pharmacology & Translational Science scope below.
ACS Pharmacology & Translational Science Scope
ACS Pharmacology & Translational Science publishes high-quality, innovative research across the broad spectrum of biological sciences—from basic and molecular sciences to translational preclinical studies. Its editors also consider clinical studies that address novel mechanisms of action and methodological papers that provide innovation and advance translation.
The journal’s editors give priority to studies that fully integrate basic pharmacological and/or biochemical findings into physiological processes that have translational potential in a broad range of biomedical disciplines. Therefore, studies that employ a complementary blend of in vitro and in vivo systems are of particular interest, but they will consider all innovative research with articulated translational relevance.
ACS Pharmacology and Translational Science does not publish research on biological extracts that have unknown concentration or unknown chemical composition.
If you have questions about the scope and/or about publishing in ACS Pharmacology & Translational Science, please contact Editor-in-Chief Craig Lindsley at email@example.com.